Exchange Traded Concepts LLC Grows Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Exchange Traded Concepts LLC increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 91.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,796 shares of the biopharmaceutical company’s stock after acquiring an additional 1,337 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Halozyme Therapeutics were worth $160,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of HALO. Handelsbanken Fonder AB increased its stake in shares of Halozyme Therapeutics by 76.9% during the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares in the last quarter. TD Asset Management Inc grew its stake in shares of Halozyme Therapeutics by 28.1% in the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock worth $103,379,000 after buying an additional 557,350 shares during the last quarter. Boston Trust Walden Corp bought a new position in Halozyme Therapeutics during the 2nd quarter valued at approximately $23,211,000. Swedbank AB purchased a new position in Halozyme Therapeutics during the first quarter valued at $13,927,000. Finally, Epoch Investment Partners Inc. boosted its holdings in Halozyme Therapeutics by 23.3% in the first quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after acquiring an additional 270,579 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HALO has been the subject of several analyst reports. Benchmark restated a “buy” rating and set a $60.00 price target on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $58.00 to $62.00 in a research note on Monday, October 7th. TD Cowen upped their target price on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday. Finally, JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price objective for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $60.44.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $40,063,244.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the transaction, the chief executive officer now owns 676,744 shares in the company, valued at $40,063,244.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Matthew L. Posard sold 9,881 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the sale, the director now directly owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 99,881 shares of company stock worth $5,721,034 in the last quarter. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $51.77 on Tuesday. The stock has a market capitalization of $6.59 billion, a price-to-earnings ratio of 21.39, a PEG ratio of 0.49 and a beta of 1.27. Halozyme Therapeutics, Inc. has a 1-year low of $32.83 and a 1-year high of $65.53. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21. The business’s fifty day moving average price is $58.61 and its 200-day moving average price is $51.38.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. Halozyme Therapeutics’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.68 earnings per share. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.